Chen GB, Wu F, Tang RM, Chen LJ. Limitations and enhancement opportunities for variceal rebleeding prediction model in patients with cirrhosis. World J Gastroenterol 2025; 31(8): 102841 [DOI: 10.3748/wjg.v31.i8.102841]
Corresponding Author of This Article
Long-Jiang Chen, MD, PhD, Department of Hepatobiliary Surgery, Affiliated Yijishan Hospital of Wannan Medical College, No. 92 Ochre West Road, Wuhu 241000, Anhui Province, China. clj2023@wnmc.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Guang-Bin Chen, Rong-Mei Tang, Department of Hepatobiliary Surgery, The Second People's Hospital of Wuhu, Wuhu Hospital Affiliated to East China Normal University, Wuhu 241000, Anhui Province, China
Guang-Bin Chen, Graduate School, Wannan Medical College, Wuhu 241000, Anhui Province, China
Fei Wu, Department of Anesthesiology, Fudan University Shanghai Cancer Center Xiamen Hospital, Xiamen 361000, Fujian Province, China
Long-Jiang Chen, Department of Hepatobiliary Surgery, Affiliated Yijishan Hospital of Wannan Medical College, Wuhu 241000, Anhui Province, China
Co-first authors: Guang-Bin Chen and Fei Wu.
Co-corresponding authors: Rong-Mei Tang and Long-Jiang Chen.
Author contributions: Chen GB and Wu F contributed equally to this work and share first authorship, participated in drafting the manuscript; Chen LJ and Tang RM contributed to conceptualization, reviewing, and editing; Chen GB, Wu F, Tang RM, and Chen LJ were involved in critical revision for important intellectual content; all authors have read and approve the final manuscript.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Long-Jiang Chen, MD, PhD, Department of Hepatobiliary Surgery, Affiliated Yijishan Hospital of Wannan Medical College, No. 92 Ochre West Road, Wuhu 241000, Anhui Province, China. clj2023@wnmc.edu.cn
Received: November 7, 2024 Revised: December 31, 2024 Accepted: January 11, 2025 Published online: February 28, 2025 Processing time: 83 Days and 23.1 Hours
Abstract
A multicenter study recently published introduced a novel prognostic model for predicting esophagogastric variceal rebleeding after endoscopic treatment in patients with cirrhosis. The model incorporated six readily available clinical variables—albumin level, aspartate aminotransferase level, white blood cell count, ascites, portal vein thrombosis, and bleeding signs—and demonstrated promising predictive performance. However, limitations, including the retrospective design and exclusion of patients with hepatocellular carcinoma, may affect the generalizability of the model. Additionally, further improvement is needed in the model’s discrimination between intermediate- and high-risk groups in external. Prospective validation and inclusion of additional variables are recommended to enhance predictive accuracy across diverse clinical scenarios.
Core Tip: A novel prognostic model for predicting esophagogastric variceal rebleeding after endoscopic treatment in patients with cirrhosis demonstrated excellent predictive performance using six clinical variables. Despite its promise, limitations, including the retrospective design and hepatocellular carcinoma patient exclusion, necessitate prospective validation and additional variable incorporation to enhance clinical utility across risk categories.
